Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
Sign Up to like & getrecommendations! Published in 2020 at "EClinicalMedicine"
DOI: 10.1016/j.eclinm.2020.100290
Abstract: Background Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10–19 years) with injectable-free regimens containing these drugs in Khayelitsha, South Africa.… read more here.
Keywords: delamanid; bedaquiline delamanid; treatment; regimens containing ... See more keywords
In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00031-19
Abstract: Due to the natural resistance of nontuberculous mycobacteria (NTM) against multiple antibiotics, treatment of infections caused by them is often long-course and less successful. The main objective of our study was the evaluation of in… read more here.
Keywords: growing mycobacterium; nontuberculous mycobacteria; bedaquiline delamanid; vitro ... See more keywords
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.00934-2018
Abstract: The World Health Organization (WHO) estimated that 490 000 cases of multidrug-resistant (MDR) tuberculosis (TB) (defined as TB caused by Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampicin) occurred in 2016. Among them, ∼6.2%… read more here.
Keywords: bedaquiline delamanid; drug; drug resistant; tuberculosis ... See more keywords
Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.02550-2017
Abstract: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) represent a therapeutic challenge [1]. Two anti-TB agents, bedaquiline and delamanid, have been recently approved for the treatment of MDR/XDR-TB. Bedaquiline has a terminal half-life of 5.5 months,… read more here.
Keywords: delamanid; bedaquiline delamanid; multidrug resistant; exposure bedaquiline ... See more keywords
Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Mycobacteriology"
DOI: 10.4103/ijmy.ijmy_178_22
Abstract: Background: A regimen containing bedaquiline–delamanid is recommended in management of drug-resistant tuberculosis (DR TB) to increase a success rate. However, this regimen was rare in a clinical setting due to a potential risk of QT… read more here.
Keywords: review; regimen containing; bedaquiline delamanid; prolongation ... See more keywords
Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Mycobacteriology"
DOI: 10.4103/ijmy.ijmy_217_22
Abstract: Background: Drug-resistant tuberculosis (DR-TB) is a public health concern that is difficult to treat, requiring long and complex treatment with highly effective drugs. Bedaquiline and/or delamanid have already shown promising outcomes in patients with DR-TB,… read more here.
Keywords: bedaquiline delamanid; regimens containing; conversion; drug resistant ... See more keywords